Logo

Thomas Bailey

Jan 16, 2018

NanoString Technologies has appointed Thomas Bailey as chief financial officer. Bailey boasts more than 20 years of experience in life sciences and healthcare organizations. Prior to joining NanoString he served as CFO at AgaMatrix Holdings, a developer, manufacturer, and marketer of medical technologies for diabetes care. Bailey was also CFO and then a CEO at Angiotech Pharmaceuticals. Bailey also has over a decade of experience in investment banking and private equity, including at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette. He holds a BA in economics from Harvard University and and MBA from Harvard Business School.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.